
Noble E. Jarrell
Examiner (ID: 14167, Phone: (571)272-9077 , Office: P/1625 )
| Most Active Art Unit | 1699 |
| Art Unit(s) | 1625, 1699, 1622, 1624, 1609 |
| Total Applications | 1419 |
| Issued Applications | 950 |
| Pending Applications | 180 |
| Abandoned Applications | 334 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16756564
[patent_doc_number] => 10975101
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-13
[patent_title] => Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface
[patent_app_type] => utility
[patent_app_number] => 16/305357
[patent_app_country] => US
[patent_app_date] => 2017-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20544
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305357
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/305357 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | May 29, 2017 | Issued |
Array
(
[id] => 17467613
[patent_doc_number] => 11274081
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-15
[patent_title] => Process for the synthesis of ivacaftor
[patent_app_type] => utility
[patent_app_number] => 16/305280
[patent_app_country] => US
[patent_app_date] => 2017-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 4002
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 165
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305280
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/305280 | Process for the synthesis of ivacaftor | May 25, 2017 | Issued |
Array
(
[id] => 12346734
[patent_doc_number] => 09951081
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2018-04-24
[patent_title] => Chlorin e6 derivative and pharmaceutically acceptable salt thereof and process for preparing and use of the same
[patent_app_type] => utility
[patent_app_number] => 15/605620
[patent_app_country] => US
[patent_app_date] => 2017-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8956
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15605620
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/605620 | Chlorin e6 derivative and pharmaceutically acceptable salt thereof and process for preparing and use of the same | May 24, 2017 | Issued |
Array
(
[id] => 17713445
[patent_doc_number] => 11377427
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-05
[patent_title] => Triazoles for regulating intracellular calcium homeostasis
[patent_app_type] => utility
[patent_app_number] => 16/304041
[patent_app_country] => US
[patent_app_date] => 2017-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 11885
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 167
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304041
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/304041 | Triazoles for regulating intracellular calcium homeostasis | May 22, 2017 | Issued |
Array
(
[id] => 14534329
[patent_doc_number] => 20190202786
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-04
[patent_title] => PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/303211
[patent_app_country] => US
[patent_app_date] => 2017-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303211
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/303211 | Pyridine dicarboxamide derivatives as bromodomain inhibitors | May 21, 2017 | Issued |
Array
(
[id] => 12030795
[patent_doc_number] => 20170320894
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-09
[patent_title] => 'MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI'
[patent_app_type] => utility
[patent_app_number] => 15/601014
[patent_app_country] => US
[patent_app_date] => 2017-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26437
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15601014
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/601014 | Macrocyclic quinazole derivatives and their use as MTKI | May 21, 2017 | Issued |
Array
(
[id] => 17843716
[patent_doc_number] => 11433057
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => Method for improving or enhancing cognition
[patent_app_type] => utility
[patent_app_number] => 16/097750
[patent_app_country] => US
[patent_app_date] => 2017-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7096
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097750
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/097750 | Method for improving or enhancing cognition | May 18, 2017 | Issued |
Array
(
[id] => 17287062
[patent_doc_number] => 11203602
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-21
[patent_title] => Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
[patent_app_type] => utility
[patent_app_number] => 16/303217
[patent_app_country] => US
[patent_app_date] => 2017-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 12057
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303217
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/303217 | Thioester prodrugs of macrocycles as inhibitors of histone deacetylases | May 17, 2017 | Issued |
Array
(
[id] => 17452967
[patent_doc_number] => 11267812
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-08
[patent_title] => KRAS G12C inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/099398
[patent_app_country] => US
[patent_app_date] => 2017-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 82598
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 364
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16099398
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/099398 | KRAS G12C inhibitors | May 16, 2017 | Issued |
Array
(
[id] => 14343295
[patent_doc_number] => 20190153620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-23
[patent_title] => LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/302043
[patent_app_country] => US
[patent_app_date] => 2017-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 66078
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302043
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/302043 | LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | May 15, 2017 | Abandoned |
Array
(
[id] => 12057061
[patent_doc_number] => 20170333405
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-23
[patent_title] => 'CONVERGENT AND ENANTIOSELECTIVE TOTAL SYNTHESIS OF COMMUNESIN ANALOGS'
[patent_app_type] => utility
[patent_app_number] => 15/592090
[patent_app_country] => US
[patent_app_date] => 2017-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 19494
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15592090
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/592090 | Convergent and enantioselective total synthesis of Communesin analogs | May 9, 2017 | Issued |
Array
(
[id] => 16343460
[patent_doc_number] => 20200308110
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/098341
[patent_app_country] => US
[patent_app_date] => 2017-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70534
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16098341
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/098341 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | May 7, 2017 | Issued |
Array
(
[id] => 16635232
[patent_doc_number] => 10913727
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-09
[patent_title] => Modulators of the integrated stress pathway
[patent_app_type] => utility
[patent_app_number] => 16/098679
[patent_app_country] => US
[patent_app_date] => 2017-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 129894
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16098679
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/098679 | Modulators of the integrated stress pathway | May 4, 2017 | Issued |
Array
(
[id] => 14309473
[patent_doc_number] => 20190144440
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => MODULATORS OF THE INTEGRATED STRESS PATHWAY
[patent_app_type] => utility
[patent_app_number] => 16/098675
[patent_app_country] => US
[patent_app_date] => 2017-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 102605
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16098675
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/098675 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | May 4, 2017 | Abandoned |
Array
(
[id] => 14309439
[patent_doc_number] => 20190144423
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => AMIDE-SUBSTITUTED PYRIDINYLTRIAZOLE DERIVATIVES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/098308
[patent_app_country] => US
[patent_app_date] => 2017-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24685
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16098308
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/098308 | AMIDE-SUBSTITUTED PYRIDINYLTRIAZOLE DERIVATIVES AND USES THEREOF | May 1, 2017 | Abandoned |
Array
(
[id] => 14102219
[patent_doc_number] => 20190092785
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-28
[patent_title] => ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/097322
[patent_app_country] => US
[patent_app_date] => 2017-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26203
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097322
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/097322 | Enhancer of zeste homolog 2 inhibitors | Apr 30, 2017 | Issued |
Array
(
[id] => 17393331
[patent_doc_number] => 11242331
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-08
[patent_title] => Analogs of yohimbine and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/097167
[patent_app_country] => US
[patent_app_date] => 2017-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 40
[patent_no_of_words] => 56671
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 318
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097167
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/097167 | Analogs of yohimbine and uses thereof | Apr 27, 2017 | Issued |
Array
(
[id] => 17996652
[patent_doc_number] => 11497738
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => Di-substituted pyrazole compounds for the treatment of diseases
[patent_app_type] => utility
[patent_app_number] => 16/097211
[patent_app_country] => US
[patent_app_date] => 2017-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 16
[patent_no_of_words] => 50340
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 207
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097211
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/097211 | Di-substituted pyrazole compounds for the treatment of diseases | Apr 27, 2017 | Issued |
Array
(
[id] => 19011688
[patent_doc_number] => 11918589
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-05
[patent_title] => Medicament for treatment of multiple sclerosis
[patent_app_type] => utility
[patent_app_number] => 16/350297
[patent_app_country] => US
[patent_app_date] => 2017-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 44517
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 322
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16350297
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/350297 | Medicament for treatment of multiple sclerosis | Apr 26, 2017 | Issued |
Array
(
[id] => 16437039
[patent_doc_number] => 20200354365
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => COMPOUNDS AND METHODS FOR TARGETING HSP90
[patent_app_type] => utility
[patent_app_number] => 16/095411
[patent_app_country] => US
[patent_app_date] => 2017-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095411
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/095411 | Compounds and methods for targeting HSP90 | Apr 20, 2017 | Issued |